Reference information for the research peptides in the Ardent Peps catalog — mechanisms, typical study dosages, and half-lives compiled from published research literature.
For educational and research use only. This information is not medical advice. Products are not intended for human or animal consumption. Always consult a qualified healthcare professional before starting any protocol.
BPC-157
Healing/Gut
Synthetic pentadecapeptide derived from a protective protein found in gastric juice, studied for tissue repair and gut health.
BPC-157 (Body Protection Compound-157) is a 15-amino-acid fragment derived from a protein isolated from human gastric juice. Preclinical research has explored its role in accelerating repair of tendons, ligaments, muscle, and the gastrointestinal lining. Proposed mechanisms include upregulation of VEGF-mediated angiogenesis, modulation of the nitric oxide system, and interaction with growth-hormone receptor signaling in injured tissue.
Half-life:
~4 hours (systemic); local tissue effects appear longer
Research dose:
Common research protocols: 250–500 mcg 1–2x daily, subcutaneous near the area of interest, for 2–6 weeks. Alternative protocol: 300–500 mcg 3x weekly (e.g., Mon/Wed/Fri) for longer-term maintenance or mild injury research.
Protocol notes:
Schedule: subcutaneous, ideally at the same time each day; for local injury research, inject near the affected area. Start/stop: run daily protocols 2–6 weeks, then reassess; 3x-weekly maintenance can continue for several weeks if tolerated. Cautions: avoid injecting through infected or irritated skin; discontinue if redness, warmth, or persistent pain develops.
Safety & side effects
Commonly reported in research: mild injection-site redness or bruising, transient dizziness, temporary appetite changes, and mild GI upset. Theoretical concerns from limited data: influence on angiogenesis (use caution with active tumors), possible interaction with blood-pressure regulation. Not studied in pregnancy, pediatrics, or long-term human use. Stop and seek medical guidance for chest pain, severe headache, or any allergic reaction.
Combination of BPC-157 and TB-500 studied together for synergistic soft-tissue and systemic recovery effects.
This blend pairs BPC-157 (local repair, angiogenesis, GI protection) with TB-500 / Thymosin Beta-4 (actin regulation, cellular migration, systemic recovery). The combination is popular in research settings because the two peptides are thought to complement each other — BPC-157 acting more locally at the injury site, TB-500 acting more systemically on cell migration and vascular remodeling.
Half-life:
BPC-157 ~4 h; TB-500 fragment ~2–3 h (with prolonged tissue effects)
Research dose:
Typical study protocol: 250–500 mcg of each component daily or every other day, subcutaneous, over 4–6 weeks. Alternative protocol: 250–500 mcg of each component 3x weekly (e.g., Mon/Wed/Fri) for maintenance or less intensive research.
Protocol notes:
Schedule: subcutaneous, any consistent time of day; rotate sites to avoid localized irritation. Start/stop: acute research 4–6 weeks; maintenance 3x weekly may extend 8–12 weeks with breaks. Cautions: watch for local site reactions, unusual fatigue, or dizziness; stop and reassess if these occur.
Safety & side effects
Commonly reported: injection-site redness/bruising, mild lethargy in the first days of TB-500 use, transient head-rush or lightheadedness, and occasional GI upset. Theoretical concerns: both peptides influence angiogenesis and cell migration — use extreme caution with any history of cancer. Long-term human safety data is limited. Discontinue for persistent fatigue, unexplained swelling, allergic reaction, or chest discomfort.
C-terminal tripeptide fragment of alpha-MSH investigated for anti-inflammatory and gut-barrier effects.
KPV (Lysine-Proline-Valine) is the terminal tripeptide of alpha-melanocyte-stimulating hormone. It retains anti-inflammatory activity without the pigmentation effects of the parent peptide. Research has focused on modulation of NF-κB signaling, mast cell stabilization, and effects on inflammatory bowel models. Investigated routes include subcutaneous injection and oral administration for gastrointestinal targeting.
Half-life:
Short (<1 hour systemic); local effects persist longer
Research dose:
Research protocols commonly use 250–500 mcg 1x daily for 4–6 weeks. Alternative protocol: 500 mcg–1 mg 3x weekly (e.g., Mon/Wed/Fri) for maintenance or gut-focused research.
Protocol notes:
Schedule: subcutaneous or oral in research; if subcutaneous, use a consistent daily time. Start/stop: daily 4–6 week courses, or 3x-weekly maintenance up to 8–12 weeks; take planned breaks between cycles. Cautions: not for active infection or severe autoimmune flare without qualified supervision; monitor for GI upset or skin reactions.
Safety & side effects
Generally well tolerated in short studies. Possible: injection-site reactions, mild GI symptoms, skin flushing or itching, headache. Because KPV modulates immune activity, use caution with immunosuppressive therapy or active infection. Not studied in pregnancy or long-term use. Discontinue for rash, swelling, or breathing difficulty (possible hypersensitivity).
Naturally occurring copper-binding tripeptide studied for skin remodeling, wound healing, and hair follicle effects.
GHK-Cu (Glycyl-L-Histidyl-L-Lysine-copper) is a tripeptide with high affinity for copper (II) that naturally declines with age. Research has examined its role in collagen and elastin synthesis, antioxidant defense, wound remodeling, and follicle stimulation. It is commonly studied topically for skin and hair research, and via subcutaneous injection in animal models of tissue repair.
Half-life:
~1–2 hours in plasma
Research dose:
Topical research formulations: 1–3 mg/mL. Injectable research protocols: 1–2 mg subcutaneous, 3–5x weekly.
Safety & side effects
Topical: usually well tolerated; possible mild irritation, redness, or contact dermatitis — patch test first. Injectable: local site reactions, transient metallic taste, and (rarely) copper-related symptoms (nausea, headache) if overused. Avoid in Wilson's disease or any condition of copper overload. Not for use on broken or infected skin without supervision. Keep away from eyes.
Synthetic analog of alpha-MSH studied for melanogenesis and photoprotective pigmentation responses.
Melanotan-1 (afamelanotide) is a linear synthetic analog of alpha-melanocyte-stimulating hormone. It binds the MC1 receptor on melanocytes, stimulating eumelanin production. Clinical research has explored its use in erythropoietic protoporphyria (EPP) to reduce phototoxic reactions. It is more selective for MC1R than Melanotan-2 and has a cleaner side-effect profile in the studies performed.
Half-life:
~1 hour (parent); pigment effects persist for weeks
Research dose:
Common research loading: 0.5–1 mg subcutaneous daily until desired response, then 1 mg 1–2x weekly maintenance.
Safety & side effects
Commonly reported: nausea (especially early doses), facial flushing, appetite suppression, spontaneous erections, and darkening of existing moles/freckles. Any new, changing, or asymmetric mole warrants dermatology review — MSH analogs can obscure early melanoma. Not recommended with a personal/family history of melanoma or many atypical nevi. Avoid in pregnancy. Take first doses in the evening to minimize nausea.
Long-acting GLP-1 receptor agonist extensively studied for glycemic control and body-weight reduction.
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist with structural modifications giving it a long half-life and resistance to DPP-4 degradation. It enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through central pathways. Clinical trials in type 2 diabetes and obesity have shown substantial reductions in HbA1c and body weight.
Half-life:
~7 days
Research dose:
Standard clinical titration: 0.25 mg weekly x 4 wks → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, subcutaneous.
Safety & side effects
Common: nausea, vomiting, diarrhea, constipation, reflux, fatigue, and injection-site reactions — usually worst after dose escalations. Serious: pancreatitis (severe persistent abdominal pain), gallbladder disease, dehydration/kidney injury from prolonged vomiting, and hypoglycemia if combined with insulin or sulfonylureas. Boxed warning for medullary thyroid carcinoma / MEN2 in rodent studies — contraindicated with personal or family history. Avoid in pregnancy. Titrate slowly and maintain hydration and adequate protein intake.
Dual GIP/GLP-1 receptor agonist producing significant glycemic and weight-loss effects in clinical trials.
Tirzepatide is a single peptide that activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual mechanism has shown superior HbA1c reduction and weight loss compared to selective GLP-1 agonists in head-to-head clinical trials, along with improvements in lipid profiles and insulin sensitivity.
Half-life:
~5 days
Research dose:
Standard clinical titration: 2.5 mg weekly x 4 wks, then step up by 2.5 mg every 4 wks as tolerated up to 15 mg weekly, subcutaneous.
Safety & side effects
Same class-effect profile as semaglutide, often more pronounced at higher doses: nausea, vomiting, diarrhea, constipation, decreased appetite, and injection-site reactions. Serious: pancreatitis, gallbladder disease, acute kidney injury from dehydration, hypoglycemia when stacked with insulin/sulfonylureas, and vision changes in diabetics with rapid glucose drops. Same MTC/MEN2 contraindication as other GLP-1 agonists. Avoid in pregnancy. Escalate no faster than every 4 weeks and hold or reduce dose if GI symptoms are severe.
Investigational triple agonist targeting GLP-1, GIP, and glucagon receptors — the most potent weight-loss peptide in current clinical trials.
Retatrutide is a triple agonist of the GLP-1, GIP, and glucagon receptors. Adding glucagon receptor activity to the GLP-1/GIP mechanism is thought to increase energy expenditure in addition to reducing intake. Phase 2 obesity trials reported some of the largest weight reductions ever seen with a pharmaceutical agent at 48 weeks.
Half-life:
~6 days
Research dose:
Clinical trial titration: 2 mg weekly, escalated by 2–4 mg every 4 wks up to 8–12 mg weekly. Alternative approach: start at 1 mg weekly, then increase by 0.5–2 mg every 4 weeks as tolerated. Subcutaneous.
Protocol notes:
Schedule: once weekly subcutaneous, same day/time each week; take with adequate hydration. Start/stop: begin at the lowest dose; increase only if no significant nausea, vomiting, or palpitations. Stop and seek guidance if severe GI symptoms, chest pain, or rapid heartbeat occur. Cautions: contraindicated in personal/family history of medullary thyroid carcinoma or MEN2; use caution with gallbladder disease, pancreatitis, or concurrent glucose-lowering agents.
Safety & side effects
GLP-1/GIP effects: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue. Glucagon-receptor effects add: increased heart rate, mild blood pressure elevation, and transient increases in fasting glucose or liver enzymes at higher doses. Serious: pancreatitis, gallbladder disease, dehydration/kidney injury, hypoglycemia with insulin/sulfonylureas. Same MTC/MEN2 contraindication as other incretin agonists. Avoid in pregnancy, active pancreatitis, and unstable cardiovascular disease. Investigational — long-term human safety is not yet established.
Synthetic tetrapeptide studied for telomerase activation and circadian/pineal regulation.
Epitalon (Ala-Glu-Asp-Gly) is a synthetic peptide modeled after epithalamin, a pineal-gland extract studied by Russian researchers. Investigations have examined its ability to induce telomerase activity, normalize melatonin rhythms, and support markers of biological aging in animal and small human studies.
Half-life:
Very short (<30 min); biological effects persist much longer
Research dose:
Common research protocols vary widely. Low-dose: 1–3 mg daily subcutaneous for 10–20 day cycles. Mid-range: 5 mg daily for 10–20 days. Higher-end: 10 mg daily for 10–20 day cycles. Typically run 1–2 cycles per year.
Safety & side effects
Reported side effects are uncommon and mild: injection-site reactions, drowsiness (dose in the evening), vivid dreams, mild headache. Theoretical concern: telomerase activation is a proposed mechanism for cellular longevity but is also a hallmark of many cancers — avoid with any active or prior malignancy without qualified oversight. No robust long-term human safety data. Not for use in pregnancy or pediatrics.
Short synthetic peptide (Glu-Asp-Arg) studied for neuroprotective and cognitive effects.
Pinealon is a synthetic tripeptide developed from research on pineal gland peptides. Preclinical studies suggest effects on oxidative stress reduction in neurons, protection against hypoxic damage, and improvements in cognitive markers in aged animal models. It penetrates the blood-brain barrier due to its small size.
Half-life:
Very short in plasma; downstream effects last days
Research dose:
Common research protocols vary. Low-dose: 1–2 mg daily subcutaneous for 10-day cycles. Mid-range: 3–5 mg daily for 10-day cycles. Higher-end: up to 10 mg daily for 10-day cycles. Typically repeated 2–3x per year.
Safety & side effects
Very limited human safety data. Reported: injection-site reactions, mild headache, sleep changes (some report vivid dreams or lighter sleep — dose earlier in the day if this occurs). Because it acts centrally, use caution with seizure disorders, active psychiatric conditions, or CNS-active medications. Avoid in pregnancy, pediatrics, and any active malignancy.
Sterile water containing 0.9% benzyl alcohol — the standard solvent used to reconstitute lyophilized peptides.
Bacteriostatic water is sterile water for injection with 0.9% benzyl alcohol added as a bacteriostatic preservative. The preservative allows a reconstituted vial to be safely used over multiple weeks (typically up to 28 days) when refrigerated, versus sterile water which should be used within 24 hours. It is the standard diluent in peptide research for reconstituting lyophilized powder.
Half-life:
N/A — solvent
Research dose:
Use enough to achieve a workable concentration (typically 1–3 mL per vial). See our reconstitution calculator for exact dilutions.
Safety & side effects
The benzyl alcohol preservative is not appropriate for neonates ("gasp syndrome") and should be avoided in pregnancy at large volumes. Rare hypersensitivity to benzyl alcohol can cause local irritation. Keep the vial refrigerated after opening, wipe the stopper with alcohol before each draw, and discard 28 days after first puncture or sooner if cloudy, discolored, or contaminated. Do not use if the seal is compromised.
